Euroimmun is modernizing its brand appearance Our company has undergone significant developments in recent years. This will now also be reflected in our visual appearance. At the ADLM in Chicago (July 27–31, 2025), we will show you our new, modernized look for the first time, underlining our innovative power and our international orientation. But, of
Press release, March 3rd 2025 Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s
At the end of last year, EUROIMMUN and Xpedite Diagnostics announced the start of a strategic partnership. Now the time has come: EUROArray SwiftX-traction is a rapid extraction procedure enabling the isolation of pathogen DNA for further analysis using EUROIMMUN’s EUROArrays. It has been especially developed for EUROIMMUN and is now approved worldwide for diagnostic
Press release October 2nd 2024 APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is
Press release Lübeck, 25 April 2024 Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This collaboration brings together EUROIMMUN’s extensive distribution network and support infrastructure with ALPCO-GeneProof’s
